American Cancer Society issues new prostate cancer screening guidelines
The new recommendations suggest biennial blood tests for men aged 50 to 69 at average risk for the disease.
The American Cancer Society (ACS) has released new guidelines for prostate cancer screening, reversing recommendations that were in place for 16 years, according to the New York Post. The organisation now recommends prostate-specific antigen (PSA) blood tests every two years for men aged 50 to 69 who are at average risk.
For Black men or those with a family history of prostate cancer, the ACS recommends starting screening at age 45 with annual testing. This replaces previous advice where average-risk patients were told to work with doctors to decide on screening.
The ACS stated that stronger evidence since 2010 shows that PSA blood tests save lives by catching the disease earlier. Cancer epidemiologist Robert Smith said in an ACS statement that PSA testing remains the cornerstone of early detection and that there is stronger evidence of its benefits.
Smith added that better approaches now exist to catch lethal tumours while avoiding unnecessary tests for slow-growing cancers that may not require aggressive care. Clinicians have previously expressed concerns regarding patient anxiety and unnecessary treatments for slow-growing, harmless cancers.
The screening process begins with a PSA blood test. If levels are elevated, the ACS recommends a repeat test after two weeks to three months. If a second test confirms elevated levels, men should undergo an MRI or a validated biomarker test before deciding on a biopsy.
A biopsy is the only way to achieve a definitive diagnosis. If a patient is diagnosed with a low-risk cancer, the ACS says they should be offered active surveillance, which involves regular testing without treatment, as the initial option.
